ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Patrick Cunniff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7761-6810; OpenAlex author ID A5088542040; NIH RePORTER profile ID 77796923. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper, 1 grant

Papers 2

KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Co-author DOI 10.1038/s41467-025-66007-0 ↗
Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41588-024-01790-y ↗

Grants 1

Targeting of Krüppel-like Factor 5 (KLF5) in Pancreatic Ductal Adenocarcinoma F31CA278591 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christopher R. Vakoc · 2 shared papers, 2024–2025 · strength 0.43
- Paper KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. DOI 10.1038/s41467-025-66007-0 ↗
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Damianos S. Skopelitis · 2 shared papers, 2024–2025 · strength 0.43
- Paper KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. DOI 10.1038/s41467-025-66007-0 ↗
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Mikala Egeblad · 2 shared papers, 2024–2025 · strength 0.43
- Paper KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. DOI 10.1038/s41467-025-66007-0 ↗
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Diogo Maia-Silva · 2 shared papers, 2024–2025 · strength 0.43
- Paper KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. DOI 10.1038/s41467-025-66007-0 ↗
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Nicole Sivetz · 1 shared paper, 2025 · strength 0.27
- Paper KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. DOI 10.1038/s41467-025-66007-0 ↗
Camila dos Santos · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
David L Spector · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Ledong Wan · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Yunus Sahin · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Douglas T. Fearon · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Philip Moresco · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗
Adrian R. Krainer · 1 shared paper, 2024 · strength 0.16
- Paper Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. DOI 10.1038/s41588-024-01790-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.